For Healthcare Professionals - International

CoreValve OUS

TAVI Platform

Performance that Matters TAVI

Latest News


CoreValve System Significantly Outperforms Surgical Valve Replacement at 1 Year In US Pivotal Trial

Results were presented in a late breaking clinical trial session at ACC.14 with simultaneous publication in the New England Journal of Medicine. Results demonstrate how the CoreValve design delivers performance that matters most to both physicians and their patients.

US Pivotal Trial High Risk Study Results >


CoreValve US Pivotal Trial Extreme Risk Study 1 Year Outcomes Published in JACC

The results demonstrate how the CoreValve design achieves high survival rates and low rates of stroke and paravalvular leakage in complex and frail patients.

US Pivotal Trial Extreme Risk Study Results >


Now CE Marked for Valve-in-Bioprosthetic Valve

CoreValve and CoreValve Evolut—the first and only TAVI devices to receive an indication for use in degenerative surgical bioprostheses—now provide options for patients at high operative risk for redo surgery.

Learn More >


CoreValve ADVANCE 1 Year Outcomes Presented at EuroPCR

New data presented at EuroPCR 2013 shows favorable 1 year outcomes with high survival rates, low and stable rates of stroke, and significant and sustained hemodynamic improvement.

ADVANCE 1 Year Outcomes >

Latest TAVI Developments


Sign up for periodic updates